pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

3,185 catalysts · 4,728 grant · 3,350 8k filing · 2,620 approval · 2,108 device 510k · 1,692 device recall · 1,464 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 0 catalysts2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: recall×from 2025-08-14×clear all
type
  • grant4,728
  • 8k filing3,350
  • approval2,620
  • device 510k2,108
  • device recall1,692
  • device pma1,464
device adverse event
1,000
  • earnings584
  • recall565
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Aug 11, 2025

    6
    ›Aug 14, 2025approval367d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    ›Aug 14, 2025approval367d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    ›Aug 14, 2025approval367d agoLAZCLUZE (LAZERTINIB MESYLATE) — FDA approvallazertinib mesylate

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →lazertinib mesylate →fda approvals ↗
    ›Aug 14, 2025approval367d agoRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalamivantamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →amivantamab →fda approvals ↗
    ›Aug 15, 2025approval366d agoBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalBYOOVIZ

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →BYOOVIZ →fda approvals ↗
    ›Aug 15, 2025approval366d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗

    Week of Aug 18, 2025

    29
    ›Aug 18, 2025approval363d agoKESIMPTA (OFATUMUMAB) — FDA approvalKESIMPTA

    Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →KESIMPTA →fda approvals ↗
    ›Aug 18, 2025approval

    Week of Aug 25, 2025

    12
    ›Aug 25, 2025approval356d agoOPUVIZ (AFLIBERCEPT-YSZY) — FDA approvalOPUVIZ

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →OPUVIZ →fda approvals ↗
    ›Aug 26, 2025approval

    Week of Sep 1, 2025

    3
    ›Sep 2, 2025approval348d agoEPYSQLI (ECULIZUMAB-AAGH) — FDA approvalEPYSQLI

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTION. Route: SOLUTION

    full page →EPYSQLI →fda approvals ↗
    ›Sep 3, 2025approval
    ← prev
    page 1 of 64
    next →
    363d ago
    BRIUMVI (UBLITUXIMAB-XIIY) — FDA approvalublituximab

    Sponsor: TG THERAPEUTICS, INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →ublituximab →fda approvals ↗
    ›Aug 18, 2025approval363d agoBRIUMVI (UBLITUXIMAB-XIIY) — FDA approvalublituximab

    Sponsor: TG THERAPEUTICS, INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →ublituximab →fda approvals ↗
    ›Aug 18, 2025approval363d agoTECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval(atezolizumab + hyaluronidase (human recombinant))

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →(atezolizumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Aug 18, 2025approval363d agoTECENTRIQ (ATEZOLIZUMAB) — FDA approvalatezolizumab

    Sponsor: GENENTECH INC. Form: INJECTABLE. Route: INJECTION

    full page →atezolizumab →fda approvals ↗
    ›Aug 18, 2025approval363d agoVYEPTI (EPTINEZUMAB-JJMR) — FDA approvalH. Lundbeck AS

    Sponsor: Lundbeck Seattle BioPharmaceuticals, Inc.. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 19, 2025approval362d agoTECVAYLI (TECLISTAMAB-CQYV) — FDA approvalteclistamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →teclistamab →fda approvals ↗
    ›Aug 19, 2025approval362d agoTALVEY (TALQUETAMAB-TGVS) — FDA approvaltalquetamab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →talquetamab →fda approvals ↗
    ›Aug 20, 2025recall361d agoB BRAUN MEDICAL INC recall (Cls II)B. Braun Medical Inc

    0.9% Sodium Chloride Injection USP, L 8000, 1000mL Excel Container, Rx Only, Sterile, nonpyrogenic, single dose container, B. Braun Medical Inc., Bethlehem, PA 18018, NDC 0264-7800-00. — Reason: Lack of Assurance of Sterility; potential for fluid leakage at one of the weld sites. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Carvedilol Tablets, USP, 12.5 mg, 500-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd, Colvale-Bardez, Goa, 403513, India. Manufactured for Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430. NDC 68462-164-05 — Reason: CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoBreckenridge Pharmaceutical, Inc. recall (Cls II)Breckenridge Pharmaceutical Inc

    Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC 82009-032-10 — Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Carvedilol Tablets, USP, 25 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur, Dist.-Dhar, Madhya Pradesh 454 775, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 47430 NDC: 68462-165-05 — Reason: CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoB BRAUN MEDICAL INC recall (Cls II)B. Braun Medical Inc

    Lactated Ringer's Injection USP, L 7500, 1000mL Excel Container, Rx Only, Sterile, nonpyrogenic, single dose container, B. Braun Medical Inc., Bethlehem, PA 18018, NDC 0264-7750-00. — Reason: Lack of Assurance of Sterility; potential for fluid leakage at one of the weld sites. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Carvedilol Tablets, USP, 12.5 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur, Dist.-Dhar, Madhya Pradesh 454 775, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 47430, NDC 68462-164-05 — Reason: CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoAscend Laboratories, LLC recall (Cls II)Ascend Laboratories Ltd

    Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/ 40 mg, 30-count bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-501-30 — Reason: Failed Dissolution Specifications: low dissolution results — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Theophylline extended-release tablets 400mg, 100-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited, Colvale-Bardez, Goa- 403513 India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ, NDC 68462-380-01 — Reason: Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Carvedilol Tablets, USP, 3.125 mg, Packaged as: a)500-count bottle, NDC 68462-162-05; b) 100-count bottle, NDC 68462-162-01; Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd, Colvale-Bardez, Goa, 403513, India. Manufactured for Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA, NJ 07430. — Reason: CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoPfizer recall (Cls II)PFIZER INC

    Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01. — Reason: Subpotent drug — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoWestminster Pharmaceuticals LLC recall (Cls II)Westminster Pharmaceuticals LLC

    Metoprolol Tartrate Tablets, USP, 100 mg, 1000 Tablets, Rx Only, Manufactured by: Renata PLC (General Plant -2), Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, 1700 Bangladesh, Distributed by: Westminster Pharmaceuticals, LLC, Nashville, TN 37217, NDC 69367-355-10 — Reason: CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoWestminster Pharmaceuticals LLC recall (Cls II)Westminster Pharmaceuticals LLC

    Metoprolol Tartrate Tablets, USP, 50 mg, 1000 Tablets, Rx Only, Manufactured by: Renata PLC (General Plant -2), Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, 1700 Bangladesh, Distributed by: Westminster Pharmaceuticals, LLC, Nashville, TN 37217, NDC 69367-354-10 — Reason: CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoGlenmark Pharmaceuticals Inc., USA recall (Cls II)LB PHARMACEUTICALS INC

    Carvedilol Tablets, USP, 25 mg, 500-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd, Colvale-Bardez, Goa, 403513, India. Manufactured for Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430. NDC 68462-165-05 — Reason: CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 20, 2025recall361d agoMerck & Co. Inc recall (Cls II)Merck & Co., Inc.

    Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label) — Reason: Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 21, 2025approval360d agoIMCIVREE (SETMELANOTIDE ACETATE) — FDA approvalsetmelanotide

    Sponsor: RHYTHM. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →setmelanotide →fda approvals ↗
    ›Aug 21, 2025approval360d agoLEQEMBI (LECANEMAB-IRMB) — FDA approvallecanemab

    Sponsor: EISAI INC. Form: INJECTABLE. Route: INJECTION

    full page →lecanemab →fda approvals ↗
    ›Aug 21, 2025approval360d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

    Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 21, 2025approval360d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

    Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 21, 2025approval360d agoCEFAZOLIN SODIUM — FDA approvalSamson Medical Technologies LLC

    Sponsor: HIKMA FARMACEUTICA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 22, 2025approval359d agoVONJO (PACRITINIB CITRATE) — FDA approvalpacritinib

    Sponsor: SOBI. Form: CAPSULE. Route: ORAL

    full page →pacritinib →fda approvals ↗
    ›Aug 22, 2025approval359d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    355d ago
    TEPEZZA (TEPROTUMUMAB-TRBW) — FDA approvalteprotumumab

    Sponsor: HORIZON THERAPEUTICS IRELAND. Form: INJECTABLE. Route: INJECTION

    full page →teprotumumab →fda approvals ↗
    ›Aug 27, 2025approval354d agoFILSPARI (SPARSENTAN) — FDA approvalsparsentan

    Sponsor: TRAVERE. Form: TABLET. Route: ORAL

    full page →sparsentan →fda approvals ↗
    ›Aug 27, 2025recall354d agoHaleon US Holdings LLC recall (Cls III)

    Sensodyne PRONAMEL (Potassium nitrate 5%, Sodium fluoride 0.25%) Active SHIELD Toothpaste for Sensitive Teeth, Fresh Mint, Net WT 3.4OZ (96.4g) Tube, 6 tubes x 2 inners, per case, Distributed by GSK Consumer Healthcare, Warren, NJ 07059. UPC 3 10158 35691 2 — Reason: Labeling: Label Mix-up: The outer carton is labelled Fresh Mint. The tube is labelled Cool Mint/Whitening. The toothpaste inside the tube is Fresh Mint as indicated on the outer carton — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 27, 2025recall354d agoCipla USA, Inc. recall (Cls III)Cipla USA Inc

    Albuterol Sulfate, Inhalation Aerosol, 90 mcg, 200 metered Inhalations, NET CONTENT 6.7 g, Manufactured by: Cipla Ltd, Indore, SEZ, Pithampur, India; Manufactured for: Cipla USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-142-60. — Reason: Failed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 27, 2025recall354d agoPFIZER INC recall (Cls II)PFIZER INC

    Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045, USA. NDC 0409-4933-05. Case: NDC 0409-4933-10. — Reason: Lack of Assurance of Sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 27, 2025recall354d agoPFIZER INC recall (Cls II)PFIZER INC

    Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx only, Hospira, Inc., Lake Forest, IL 60045, USA, NDC 0409-6637-24. Case NDC: 00409-6637-14. — Reason: Lack of Assurance of Sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 27, 2025recall354d agoVIONA PHARMACEUTICALS INC recall (Cls II)IONIS PHARMACEUTICALS INC

    Tavaborole Topical Solution 5%, 10 mL per glass bottle, Rx Only, For Topical Use Only, Manufactured by: Zydus Lifesciences Ltd., Changodar Ahmedabad, India. Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016. NDC: 72578-102-04 — Reason: Discoloration — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 27, 2025recall354d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)ACI Healthcare USA Inc

    Carvedilol Tablets USP, 12.5 mg, 100- Tablets, (10x10) cartons, Rx Only, Packaged and distributed by Major Pharmaceuticals, Indianapolis, IN, 46268, USA, NDC 0904-7307-61 — Reason: CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 27, 2025recall354d agoTaizhou Kangping Medical Science And Technology Co., Ltd. recall (Cls II)

    BZK Antiseptic Towelette, Sterile, For External Use Only, benzalkonium chloride 0.13%, Antiseptic, 100 towelettes per carton , For Professional use, Mfg by: Taizhou Kangping Medical, Taizhou, JiangSu, China, NDC: 71310-111-01 — Reason: Lack of Assurance of Sterility. — Status: Ongoing

    full page →fda recalls ↗
    ›Aug 29, 2025approval352d agoBRIXADI (BUPRENORPHINE) — FDA approvalbuprenorphine LA

    Sponsor: BRAEBURN. Form: SOLUTION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →buprenorphine LA →fda approvals ↗
    ›Aug 29, 2025approval352d agoBILPREVDA (DENOSUMAB-NXXP) — FDA approvalBILPREVDA

    Sponsor: SHANGHAI HENLIUS BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →BILPREVDA →fda approvals ↗
    347d ago
    SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →risankizumab →fda approvals ↗
    ›Sep 3, 2025approval347d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION

    full page →risankizumab →fda approvals ↗
    $NVS150.88-0.55%
    $LBRX47.77+7.92%
    $TGTX48.74+1.67%
    $TGTX48.74+1.67%
    $LBRX47.77+7.92%
    $LBRX47.77+7.92%
    $LBRX47.77+7.92%
    $PFE26.79-0.04%
    $LBRX47.77+7.92%
    $LBRX47.77+7.92%
    $MRK135.84+0.21%
    $RYTM115.48-0.47%
    $GILD138.36+0.16%
    $PFE26.79-0.04%
    $TVTX62.14+1.16%
    $IONS57.24+2.45%
    $PFE26.79-0.04%
    $ABBV249.46-0.54%
    $ABBV249.46-0.54%